Medicare claims for genetic cancer tests face growing rejection rates

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national coverage determination that established coverage standards for NGS testing.